For questions about this article or underlying research, email help trefis.com.
Edwards Lifesciences Corp (EW) — Live Session & Technical Brief
Updated Nov 16, 2026 2:07 PM ET · Prev Close $107.15
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-0.46%) in Medical Devices
Edwards Lifesciences Corp (EW) is trading within a tight intraday band at $106.66 (-0.46%, 0.37x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, EW is outperforming the S&P 500 by +1.43%. 14-day RSI stands at 79.4, keeping momentum in a overbought regime.
For questions about this article or underlying research, email help trefis.com.
Price ($106.66) holds above both 20-day ($97.03) and 50-day ($90.77) moving averages.
Market & Sector Relative Strength
EW outperforming the S&P 500 by +1.43%Recent EW Catalyst Headlines
Verified WireEdwards Lifesciences NYSE Ew raised its 2026 sales and earnings guidance after third-quarter results exceeded management s expectations, with growth across its heart-valve businesses and regions. The medical device maker
Boston Scientific's weak Watchman demand, EP market share losses and lowered 2026 outlook raise concerns over its growth prospects. Is it time to exit?
Dick Boer Dick Boer Laurence Debroux Laurence Debroux Todd Brinton Todd Brinton November 16, 2026 Dick Boer, former President and CEO of Ahold Delhaize, proposed as new member and Vice-Chairman of Philips Supervisory Boa
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $97.03 (20-day SMA support) for directional breakout confirmation.
Technical Regime (EW)
BULLISH MA TRENDRetail & Crowd Sentiment
NeutralEdwards Lifesciences announced positive results from the Progress trial of its TAVR system, showing superiority over clinical surveillance for moderate aortic stenosis patients with at-risk features.
About Edwards Lifesciences Corp
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives …
Get Instant EW Catalyst Alerts
Receive an email alert when EW triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversEW Session & Catalyst FAQ
Why is EW stock trading near flat today?
Edwards Lifesciences Corp (EW) is trading within a tight intraday band at $106.66 (-0.46%, 0.37x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, EW is outperforming the S&P 500 by +1.43%. 14-day RSI stands at 79.4, keeping momentum in a overbought regime.
Is EW stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.37x relative volume (low participation). Our multi-factor model currently rates EW as EXTENDED. Review full valuation, quality, and timing signals on the EW Buy or Sell Decision Brief →
What is EW's intrinsic value and expected trading range?
At $106.66, EW's modeled 1-to-3 session range is $104.08 – $109.24, with a key inflection level at $97.03 (20-day SMA support). Compare current price against multi-year cash flow projections in the EW Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for EW?
RSI at 79.4 indicates overbought momentum — elevated pullback risk. EW trades at $106.66 relative to its 20-day SMA ($97.03) and 50-day SMA ($90.77), reflecting a bullish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.